RPRX PDUFA decision: Friday, November 27, 2026
…the FDA accepted its NDA for neladalkib for filing and granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) date of November 27, 2026. TEV-’408 In July 2026, Teva Pharmaceuticals (Teva) announced plans to advance TEV-’408 into a Phase 2b study in patient
Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.